Anti-HBV therapy timing and drug selection in various populations
10.3969/j.issn.1001-5256.2022.11.002
- VernacularTitle:不同人群抗HBV治疗的时机和药物选择
- Author:
Yeqiong ZHANG
1
;
Qiumin LUO
1
;
Lu WANG
2
;
Liang PENG
1
;
Zhiliang GAO
1
Author Information
1. Department of infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China
2. Second School of Clinical Medicine, Binzhou Medical University, Yantai, Shandong 264003, China
- Publication Type:Discussions by Experts
- Keywords:
Hepatitis B Virus;
Hepatitis B, Chronic;
Antiviral Agents
- From:
Journal of Clinical Hepatology
2022;38(11):2444-2447
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B virus (HBV) infection is still a serious disease threatening human health. Anti-HBV treatment is an extremely important means to reduce the threat of hepatitis B. In recent years, there has been no consensus on the timing and drug selection of anti-HBV therapy. The timing and drug selection of anti-HBV therapy in various populations are discussed in this article.
